[ad_1]
Pfizer Inc.’s stock was rallying Tuesday after the drug giant lifted its 2025 adjusted profit estimate, on the heels of a 10% jump in second-quarter revenue on strength in its Vyndaqel heart medication and its COVID-19 drugs.
[ad_2]
Source link
Pfizer boosts profit estimate, even as the drug giant absorbs tariffs
